Phase II study of simultaneous radiochemotherapy (RCT) with cisplatin/etoposide followed by consolidation chemotherapy (CT) with platin/gemcitabine for unresectable non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Fink, T. H.
Melzner, W.
Strnad, V.
Sauer, R.
Albrecht, C.
Birkenhake, S.
Ficker, J. H.
机构：
[1] Klinikum Nuremberg, Med 3, Nurnberg, Germany
[2] Univ Erlangen Nurnberg, Erlangen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18103
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of cisplatin, etoposide and concurrent radiation therapy with maintenance chemotherapy with cisplatin and gemcitabine for unresectable non-small cell lung cancer.
    Melzner, W
    Fink, TH
    Ficker, JH
    Sauer, R
    Strnad, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 688S - 688S
  • [2] Phase II trial of gemcitabine and cisplatin (GC) as neoadjuvant chemotherapy in unresectable stage III non-small cell lung cancer (NSCLC).
    Crino, L
    Mazzoni, F
    Maestri, A
    Calandri, C
    Selvaggi, G
    Scagliotti, GV
    De Marinis, F
    Gregorc, V
    Darwish, S
    Tonato, M
    ANNALS OF ONCOLOGY, 2000, 11 : 108 - 108
  • [3] Gemcitabine-cisplatin combination in non-small cell lung cancer (NSCLC). A phase II study
    Crino, L
    Seagliotti, G
    Marangolo, M
    Figoli, F
    Clerici, M
    DeMarinis, F
    Salvati, F
    Cruciani, G
    Dogliotti, L
    Cocconi, G
    Paccagnella, A
    Adamo, V
    Incoronato, P
    Scarcella, L
    Mosconi, AM
    Tonato, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1064 - 1064
  • [4] Gemcitabine combined with cisplatin in non-small cell lung cancer (NSCLC): A phase I/II study
    Steward, WP
    Dunlop, DJ
    Cameron, C
    Talbot, DC
    Kleisbauer, JL
    Thomas, P
    Guerin, JC
    Perol, M
    Sanson, C
    Dabouis, G
    Lacroix, H
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1081 - 1081
  • [5] Gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC): A phase II study
    Orlandi-Jorquera, L
    Orlandi, F
    Galaz, P
    Gamargo, C
    Salman, P
    Yanez, M
    ANNALS OF ONCOLOGY, 1998, 9 : 101 - 101
  • [6] Cisplatin and gemcitabine (GC) as neoadjuvant therapy of stage III unresectable non-small cell lung cancer (NSCLC):: A phase II study
    Mazzoni, F
    Di Stefano, A
    Maestri, A
    Calandri, C
    Mosconi, AM
    De Marinis, F
    Scagliotti, GV
    Selvaggi, G
    Crinò, L
    Tonato, M
    ANNALS OF ONCOLOGY, 2000, 11 : 8 - 8
  • [7] A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer
    Driesen, Peter
    Lambrechts, Marc
    Kraaij, Kees
    Soldatenkova, Victoria
    Chouaki, Nadia
    Colinet, Benoit
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2013, 5 (03) : 159 - 168
  • [8] Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B Unresectable Non-small Cell Lung Cancer
    Movsas, Benjamin
    Langer, Corey J.
    Ross, Helen J.
    Wang, Luhua
    Jotte, Robert M.
    Feigenberg, Steve
    Xu, Feng
    Huang, Chao H.
    Monberg, Matthew J.
    Obasaju, Coleman K.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : 673 - 679
  • [9] Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small cell lung cancer
    Lee, D
    Cho, K
    Han, J
    Pyo, H
    Kim, H
    Yoon, S
    Lee, J
    LUNG CANCER, 2005, 49 : S170 - S171
  • [10] Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation (CCR) with biweekly gemcitabine in unresectable stage III non small cell lung cancer (NSCLC):: Final results of a phase II study
    Blanco, R
    Solé, J
    Nogué, M
    Montesinos, J
    Gallardo, E
    Vadell, C
    Mesía, C
    Algara, M
    Terrasa, J
    LUNG CANCER, 2005, 49 : S77 - S77
12345